LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

PCR Biosystems Ramps Up Production of Critical Enzyme Mix for COVID-19 Tests

By LabMedica International staff writers
Posted on 10 Apr 2020
Print article
Image: qPCRBIO Probe 1-Step Go (Photo courtesy of PCR Biosystems Ltd.)
Image: qPCRBIO Probe 1-Step Go (Photo courtesy of PCR Biosystems Ltd.)
PCR Biosystems Ltd. (London UK) is continuing to scale up operations to ensure the critical enzyme mix for COVID-19 tests remains available to the UK and global healthcare systems, as the demand for testing rises. To meet the current and upcoming requirements and ensure supply chain security, the company has already significantly increased – and will continue to increase – manufacture of qPCRBIO Probe 1-Step Go and all other critical reagents for rapid and sensitive RT-qPCR.

PCR Biosystems is a manufacturer of PCR kits and reagents for molecular biology diagnostics and research. The company has developed a range of PCR reagents that maximize speed and sensitivity from the simplest to most challenging of reactions. The company’s portfolio covers a broad range of applications including long range PCR, high fidelity PCR, and molecular diagnostic PCR.

The company’s qPCRBIO Probe 1-Step Go is a universal probe kit designed for fast and sensitive probe-based RT-qPCR, and a recommended product for COVID-19 diagnostic tests, supporting the detection, quantification and typing of the SARS-CoV-2 virus. All that is required is the addition of specific primers and probes, together with the swab extract and water. qPCRBIO Probe 1-Step Go is compatible with all qPCR instruments and is engineered for use on a wide range of probe technologies, including TaqMan, Scorpions and molecular beacon probes. In March 2020, PCR Biosystems introduced bulk pack sizes of the product to further support customers in high-throughput COVID-19 testing. The measures already implemented by PCR Biosystems will ensure the company remains able to supply the healthcare system with the RT-qPCR reagents and expertise required in the global fight against COVID-19.

“These are unprecedented times, and, as a global PCR company, we are ideally placed to support the scientific and healthcare communities in their response to COVID-19. When the enormity of COVID-19 testing requirements became apparent, we immediately started scaling up production of the critical components,” said Alex Wilson, Co-Founder of PCR Biosystems. “We already have capacity to supply four million reactions’ worth of reagent every day – and we have the option to scale up further if needed to ensure we can always meet global demand.”

Related Links:
PCR Biosystems Ltd.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more